P516 Discrepancy between fecal biomarkers and their intestinal gene expression in ulcerative colitis: Results from an anti-IL-13 antibody study
Walter Reinisch(Medical University of Vienna), Fabio Cataldi(Pfizer (United States)), Tara McDonnell Moorehead(Clinical Solutions), Julián Panés(Hospital Clínic de Barcelona), Michelle Hinz(Pfizer (United States)), Gail M. Comer(Pfizer (United States)), Fei Hua(Soochow University), Karen Page(Pfizer (United States)), Sandeep Khurana(Çevre, Şehircilik ve İklim Değişikliği Bakanlığı)
Cited by 4
Related Papers
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals
|Nature Metabolism|2020|775
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
|The Lancet|2022|383